| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 London, Ontario
2 Hamilton, Ontario
| Article appraised |
|---|
|
|
|---|
| Structured abstract |
|---|
|
|
|---|
Data sources: Studies were identified by computerized searches of Current Contents (19956), EMBASE (198096), MEDLINE (196696), and the Cochrane Library (1988) using the keywords "regional anesthesia", "regional anaesthesia", "spinal", or "epidural" and the Cochrane Collaboration search terms for randomized trials. Citation review of reference lists and hand search of conference proceedings were also performed.
Study selection: Studies were selected if they were trials of patients randomized to intraoperative neuraxial blockade (epidural or spinal anesthesia) or general anesthesia. The neuraxial anesthesia group could also receive general anesthesia concurrently; the general anesthesia group could also receive postoperative neuraxial blockade.
Data extraction: Data were extracted on trial design, interventions, patient characteristics, and events. The main outcomes were all cause mortality, deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), transfusion requirements, pneumonia, other infections, respiratory depression, and renal failure.
Main results: One hundred forty-one trials with a total of 9559 patients met the inclusion criteria. Neuraxial blockade significantly reduced 30-day all cause mortality, DVT, PE, transfusion requirements, and respiratory depression (Table I
). Reductions were noted in MI, stroke, wound infections, and renal failure, but these were not statistically significant. There were no differences in the number of deaths between 30 days and six months after surgery.
|
Funding: Funding: Health Research Council of New Zealand, Astra Zeneca.
Correspondence:Dr. Rodgers, Clinical Trials Research Unit, Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand. Email: a.rodgers{at}ctru.auckland.acnz
| Commentary by S. Ganapathy |
|---|
|
|
|---|
Although the studies are reported over 30 years during which there were evolving changes in diagnostic criteria, management strategies, anesthesia techniques and surgery that could affect outcome, it is likely they are evenly distributed between the groups. This is particularly true for cardiovascular events, DVT and pulmonary embolism. The authors fail to comment on the important role of preoperative risk stratification on outcome. Studies included were from many countries but this only makes the report more valuable.
Why did we not see these benefits of regional anesthesia in individual studies? This article clearly demonstrates the role of sample size in clinical trials. For a rate of event of 0.08 (=0.05 and ß=0.8), the number of patients required per group to show a 25% difference in outcome is 2,521 and for a 50% difference is 534.1 The largest studies addressing this issue had randomized only a tenth of this number.24
Although the authors comment that there was no clear difference between different surgical groups on total mortality, Table II in their paper reveals that orthopedic and vascular patients contribute the entire mortality difference of 30%. Vascular patients contributed little to the benefits seen with reduction in DVT, pulmonary emboli, myocardial infarction and perioperative transfusion requirements and therefore the reduction in their mortality could be attributed to reduction in infective and respiratory complications. The intraoperative death risk is 3 times higher in this group with general anesthesia.
Finally, the lack of benefit seen in general surgical and urological patients and lumbar epidurals may be interlinked. Perhaps the use of lumbar epidurals for general or abdominal surgery may be detrimental to outcome. A subgroup analysis of this factor is lacking in this paper. It will be difficult, if not impossible, not to combine light general anesthesia with neuraxial blocks for abdominal surgery. As per Rodgers et al's paper, addition of general anesthesia seems to take away the benefits of regional anesthesia.
This meta-analysis is much awaited preliminary evidence in favour of regional anesthesia and indicates the need for large multicentre randomized prospective trials.
| References |
|---|
|
|
|---|
2
Davis FM, Woolner DF, Frampton C, et al. Prospective multicentre trial of mortality following general or spinal anaesthesia for hip fracture surgery in the elderly. Br J Anaesth 1987; 59: 10808.
3
Valentin N, Limholt B, Jensen JS, Hejgaard N, Kreiner S. Spinal or general anaesthesia for surgery of the fractured hip? A prospective study of mortality in 578 patients. Br J Anaesth 1986; 58: 28491.
4 Bode RH Jr, Lewis K, Zarich S, et al. Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia. Anesthesiology 1996; 84: 313.[Medline]
| Commentary by D.N. Buckley |
|---|
|
|
|---|
The systematic review reported by Rodgers et al goes some considerable way in dispelling my skepticism. It addresses one of the most pressing issues in current anesthetic practice whether or not our individual choices in anesthetic technique have important effects upon patient outcome. It should have a major effect on perioperative medical practice. It provides information that probably would not have been gathered in any other way, and which is useful to the work-a-day anesthesiologist. It is intellectually rigorous. This is the information that we require daily to support and guide our practice. We not only face budgetary constraints and the never-ending drive of the surgeon to start sooner ("Why do we always have to wait for anesthesia? Those epidurals take so long!"), but we also interact with other elements of perioperative care such as prophylaxis of deep vein thromboembolism (DVT). The US Food and Drug Administration Public Health Advisory concerning low molecular weight heparins (LMWH)2 states, in part, that "practitioners should consider fully the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis"2 (italics mine). The American Society of Regional Anesthesia consensus conference3 similarly advises careful consideration of risks versus benefits of regional anesthesia in conjunction with LMWH. A major problem, to date, has been that we have "believed" that a benefit existed, but we have had no evidence that such benefit existed because hard clinical outcomes such as all- cause mortality or major morbidity are just too rare in current anesthetic practice to appear in manageable clinical trials. Trials that support the use of low molecular weight heparins for DVT prophylaxis, on the other hand, have consistently been of sufficient power (in part because of the financial stakes) to support their use as effective "state of the art" thromboprophylactic agents. Thus one component of perioperative management directs another on the basis of superior quality evidence. With the information presented by Rodgers et al, the discussion of perioperative risk and benefit for patients can be carried out with a better perspective on the total picture; rational discussions can be had with other perioperative physicians. All anesthesiologists should become familiar with this work in its description of our practice and its implications for perioperative management.
| References |
|---|
|
|
|---|
2 US Department of Health and Human Services. FDA Public Health Advisory. Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. December, 1997. Available from: http://www.fda.gov/medwatch/safety/1997/antico.html
3 Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998: 23(Suppl. 2): 16477.[Medline]
This article has been cited by other articles:
![]() |
C. Sinclair and N. Eipe Recurrent postoperative deep vein thrombosis in a patient with obstructive sleep apnea and malignant hyperthermia susceptibility Can J Anesth, December 1, 2007; 54(12): 1032 - 1033. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |